Delivery Order SPE2DB22D2206-SPE2DB25FJE23
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,592.44 to AmerisourceBergen Drug Corp for Nucynta ER 50 mg tablets (60-count supply) on July 25, 2025, with an ultimate completion date of July 28, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Nucynta ER 150 mg tablets (60-count units) with a ceiling value of $1,110.11. This firm fixed-price delivery order, which is not set-aside, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be performed at AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Nucynta ER 100 mg tablets (60-count units) valued at $2,944.08 under a firm fixed-price contract. This delivery order represents a child contract issued against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a $999,999,999.00 ceiling and extends through December 2026. The award was competitively...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Nucynta ER 50 mg tablets (60-count), with a contract ceiling value of $1,398.37. This is a firm fixed-price delivery order with no set-aside designation, demonstrating competitive award to the contractor. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of July 23, 2025. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $2,244.18 to AmerisourceBergen Drug Corp for the supply of Nucynta ER 250 mg tablets (60-count) on July 31, 2025, with completion targeted for August 1, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The award carries no set-aside...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for supply of Nucynta 75 mg tablets (100 count) valued at $1,432.38 under a firm fixed price contract. The award, issued on July 30, 2025, with a completion date of July 31, 2025, represents a small-value pharmaceutical procurement with no set-aside designation. Performance will take place at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $3,514.46 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the provision of NUCYNTA ER 100 MG TABLET 60S. This delivery order is part of a larger indefinite delivery contract (IDC) held by Amerisourcebergen Drug Corp with DLA, valued at up to $999,999,999.00 and running through December 31, 2025. The IDC serves as the primary vehicle for Amerisourcebergen Drug Corp...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Nucynta 50 mg tablets (100 count) with a ceiling value of $1,225.04. This firm fixed-price delivery order, with an ultimate completion date of July 23, 2025, represents a direct fulfillment of pharmaceutical needs through the federal medical supply chain. The contract is not set-aside and was competitively awarded, reflecting AmerisourceBergen's established capability as a...
- The Defense Logistics Agency awarded a delivery order valued at $3,761.86 to AmerisourceBergen Drug Corp for 60 tablets of Nucynta ER 200 mg, a prescription opioid pain medication. The contract, executed on July 28, 2025, with an ultimate completion date of July 29, 2025, employs firm fixed-price pricing with no set-aside designation, indicating competitive award status. Performance will be conducted at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order contract by the Defense Logistics Agency (DLA) on July 24, 2025, for the supply of Nucynta ER 50 mg tablets in quantities of 60 units. The contract carries a ceiling value of $1,414.00 and features firm fixed pricing with an ultimate completion date of July 25, 2025. This is a non-set-aside award issued competitively and represents a child contract under AmerisourceBergen's existing...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJE23Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Nucynta ER 100 mg tablets (60-count units) under a firm fixed-price contract valued at $1,472.04. The award, issued on July 31, 2025, with an ultimate completion date of August 1, 2025, represents a non-competitive delivery order executed without set-aside provisions. This transaction falls under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX, which carries a ceiling value of $999,999,999.00 through December 2026 and serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, supplies a wide range of pharmaceutical products and medical commodities to support federal medical procurement needs, particularly for military and veteran healthcare systems. The company's performance under the SPE2DX IDC demonstrates its capability to fulfill diverse pharmaceutical requirements across multiple therapeutic domains, with this specific delivery order representing one of numerous transactions supporting DLA's medical supply chain operations. The vendor's extensive portfolio of federal contracts reflects its role as a critical provider within the Defense Health Agency's pharmaceutical procurement ecosystem.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 7/31/25 |